TIAA CREF Investment Management’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

TIAA CREF Investment Management’s Portfolio JNCE Stock Details JNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	$1.11M	Buy	178,427 +153,140	+606%	+$740K	﹤0.01%	2274
2018 Q4	$85K	Hold	25,287	–	–	﹤0.01%	2972
2018 Q3	$164K	Sell	25,287 -2,555	-9%	-$19K	﹤0.01%	3015
2018 Q2	$213K	Sell	27,842 -916	-3%	-$13.2K	﹤0.01%	3025
2018 Q1	$643K	Hold	28,758	–	–	﹤0.01%	2640
2017 Q4	$367K	Sell	28,758 -13,434	-32%	-$197K	﹤0.01%	2894
2017 Q3	$657K	Sell	42,192 -22,340	-35%	-$316K	﹤0.01%	2711
2017 Q2	$905K	Buy	64,532 +54,119	+520%	+$1.16M	﹤0.01%	2593
2017 Q1	$229K	Buy	+10,413	New	+$221K	﹤0.01%	2969

Other funds holding JNCE

TGI

TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return

TGI

TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

TIAA CREF Investment Management's JNCE Position: Q1 2019 in Review

TIAA CREF Investment Management increased its Jounce Therapeutics, Inc. Common Stock (JNCE) stake by 606% in Q1 2019, buying an estimated $740K and bringing the position to 178,427 shares worth $1.11M. The position accounts for ﹤0.01% of the portfolio, ranked #2274.

TIAA CREF Investment Management first reported a position in JNCE in Q1 2017 and has held it in 9 quarters since. 80 funds tracked by Wall St. Rank hold JNCE as of Q1 2019.

TIAA CREF Investment Management held 178,427 shares of Jounce Therapeutics, Inc. Common Stock worth $1.11M as of Q1 2019.
TIAA CREF Investment Management bought 153,140 Jounce Therapeutics, Inc. Common Stock shares in Q1 2019, an estimated $740K.
Jounce Therapeutics, Inc. Common Stock made up ﹤0.01% of TIAA CREF Investment Management's portfolio in Q1 2019, its #2274 holding.
TIAA CREF Investment Management first reported a position in Jounce Therapeutics, Inc. Common Stock in Q1 2017 and has held it in 9 quarters since.
80 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.